Table of Contents
The analysis in this research service is based on the following:
•Information collected through discussions with market participants
•Information from secondary pharmaceutical companies, medical device companies involved in drug delivery systems, related Web sites, and other credible sources
•Public announcements from key market leaders, suppliers, new market entrants, and other companies
•Frost & Sullivan’s published research and market and technology expertise All market figures and shares listed within this report are Frost & Sullivan's assessments based on the research conducted. For Market Engineering research, Frost & Sullivan utilises tried and tested marketing techniques to provide the research structure and an easy format to compare growth across different countries and markets over a specific time period. This project uses primary (telephone) and secondary (published and online material) research as the principal methods of data gathering. Interviews for this project primarily focus on the respondent types outlined below:
•Key regulatory bodies
•Frost & Sullivan published research services
•Decision Support Databases
•Country Industry Forecasts
•Annual reports published by companies
•In 2014, the global injectable drug delivery market was estimated to be $ x billion, of which, diabetes injectables made up x % at $ x billion.
•The global oral drug delivery market was valued at $ x billion in 2014 with oral diabetes drugs comprising x % ($ x billion).
•Injectable pens form the most attractive drug delivery sector in the diabetes drug market; major drug companies are planning to launch pipeline products between 2015 and 2020 (e.g., U x and IDegLira).
•Oral insulin and other forms of needleless drug delivery systems, such as Omarigliptin (MK-3102), Metformin Fixed Dose Combination (FDC), and Dallresp (roflumilast), are expected to enter the diabetes market by the end of 2019.
•Insulin inhalers such as Afrezza® from MannKind Corporation are expected to launch in Q1 2015. Insulin patches are under development and could become game changers in the diabetes drug delivery market.
•In 2015, four major diabetes drugs will enter the US and European markets, namely, Afrezza® (MannKind’s inhalable drug distributed by Sanofi), Tanzeum (injectable pen), Xigduo XR (oral), and Xultophy (injectable pen).
•Depending on the acceptance of inhalable diabetes drug delivery, the global diabetes drug market can expect increased investment in the future. At present, with the exception of one inhalable drug approved by the Food and Drug Administration (FDA), there are no other inhalable products in the diabetes clinical pipeline.
Unmet Needs in the Diabetes Drug Delivery Market
•Limited drug delivery options available to patients (oral or injectable)
•Drug discontinuity in aged populations due to memory loss and reimbursement costs
•Rise in patient demand for needleless diabetes drug delivery
•Disease not under control due to poor patient-adherence to medication regimens and lack of proper disease management
•Oral insulin and other alternate forms to be available after 2 to 3 years
•Efficacy of new drug delivery systems still debatable
•Difference in insurance schemes from region to region
•Variations in price regulations in important markets
Scope and Segmentation
•This study looks at the global diabetes drug delivery market and is segmented as follows:
oInjectable diabetes drug delivery market
oOral diabetes drug delivery market
oTransdermal patches and inhalable diabetes drug delivery market*
oOther diabetes drug deliveries market (implantable devices and artificial pancreas)**
•The study is also segmented by region:
oThe United States
Key Questions This Study Will Answer
Which is the most preferred diabetes drug delivery system?
What are the market trends that will impact existing diabetes drug delivery systems?
What are the key companies to watch in the upcoming years?
What are the new emerging diabetes drug delivery systems?
What are the key drivers and restraints in the diabetes drug delivery market?
Which are the main competitors in each type of diabetes drug delivery market?
Get Industry Insights. Simply.
Talk to Ahmad
+1 718 618 4302
Global Pulmonary Drug Delivery Devices Market: Overview This report on pulmonary drug delivery devices studies the current as well as future prospects of the market globally. The stakeholders of this report ...
The global injectable drug delivery market, in terms of value, is projected to reach USD 624.50 billion by 2021 from USD 362.38 billion in 2016, at a CAGR of 11.5% during the forecast period. The increase ...
The global pulmonary drug delivery market is projected to reach USD 52.37 billion by 2021 from USD 36.10 billion in 2016, at a CAGR of 6.5% during the forecast period. Increasing preference of pulmonary ...